School of Pharmacy, University of Otago, 9054, Dunedin, New Zealand.
AAPS J. 2012 Dec;14(4):860-71. doi: 10.1208/s12248-012-9398-6. Epub 2012 Sep 7.
Facing the increasing number of poorly water-soluble drugs, pharmaceutical scientists are required to break new grounds for the delivery of these pharmaceutically problematic drugs. Lipid-based drug delivery systems (LBDDS) have received increased interest as a novel drug delivery platform during the last decades and several successfully marketed products have shown the potential for LBDDS. However, there exists a discrepancy between the clear need for innovative delivery forms and their rational design. In the case of LBDDS, this can be attributed to the complexity of LBDDS after administration. Unlike conventional formulations, LBDDS are susceptible to digestion in the gastrointestinal tract, the interplay of delivery system, drug and physiology ultimately effecting drug disposition. In vitro lipolysis has become an important technique to mimic the enzymatic degradation. For the better understanding of how LBDDS promote drug delivery, in vitro lipolysis requires advanced characterisation methods. In this review, the physiological background of lipid digestion is followed by a thorough summary of the techniques that are currently used to characterise in vitro lipolysis. It would be desirable that the increasing knowledge about LBDDS will foster their rationale development thereby increasing their broader application.
面对越来越多的水溶性差的药物,制药科学家需要为这些药物的给药开辟新的途径。在过去几十年中,基于脂质的药物传递系统(LBDDS)作为一种新型药物传递平台受到了越来越多的关注,并且已经有几种成功上市的产品显示出了 LBDDS 的潜力。然而,在创新的给药形式的明确需求和它们的合理设计之间存在差距。在 LBDDS 的情况下,这可以归因于给药后 LBDDS 的复杂性。与传统制剂不同,LBDDS 易在胃肠道中消化,传递系统、药物和生理学的相互作用最终影响药物处置。体外脂肪分解已成为模拟酶降解的重要技术。为了更好地了解 LBDDS 如何促进药物传递,体外脂肪分解需要先进的特征化方法。在这篇综述中,首先介绍了脂质消化的生理背景,然后详细总结了目前用于体外脂肪分解特征化的技术。随着对 LBDDS 的了解不断增加,将促进其合理开发,从而扩大其更广泛的应用。